SOLICITATION NOTICE
68 -- Montanide
- Notice Date
- 4/12/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Room 604, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-20038-NG
- Response Due
- 4/22/2002
- Archive Date
- 5/7/2002
- Point of Contact
- Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
- E-Mail Address
-
holdcram@exchange.nih.gov, rasmusc@mail.nih.gov
- Description
- The National Cancer Institute (NCI) Pharmaceutical Management Branch (PMB) plans to procure Montanide ISA-151 from the sole manufacturer, Seppic, Inc. Suite 225, 30 Two Bridges Road, Fairfield, New Jersey 02004. The North American Industry Classification System code is 325412 and the business size standard is 500 employees. The Pharmaceutical Management Branch currently provides montanide ISA-151 Sterile Injection, 3 mL ampules (NSC 675756) for twenty-two studies involving hundreds of study participants. This is an investigational agent that is not approved for commercial distribution in the United States. This agent is being studied as an adjuvant to other agents in various types of cancer. Montanide ISA (incomplete seppic adjuvant)-151 Sterile Injection, 3 mL ampules (NSC 675756) is an experimental substance, which is intended to boost immune reactions to other experimental peptides. It is not commercially available in the United States. There are no generic equivalents, nor are there therapeutically equivalent agents that could be used in its place. The product should be delivered within 72 hours of ordering. The ampules must have a minimum expiration date of 18 months at the time of delivery to the NCI. A Certificate of Analysis (CoA) must be provided and all ampules must be from the same lot. Changing variables at this time will be detrimental to the experiment in progress. Seppic, Inc. is the only known source to the NCI that can provide the aforementioned substance. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and nay other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 1:00 PM EST, on April 22, 2002. For further information please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@exchange.nih.gov or Caren Rasmussen at rasmussc@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed copies of capability statements will be accepted. If submitting capability statement on or before April 17, 2002, please mail to Malinda Holdcraft, NIH/NCI/RCB, 6116 Executive Blvd. Suite 205, Rockville, Maryland 20852. If mailing on or after April 18, 2002, please mail to Malinda Holdcraft, NIH/NCI/RCB, 6120 Executive Blvd. 6th floor suite 6072, Rockville, Maryland 20852-7194. ***Please note, the NCI/RCB will be moving April 18 - April 19, 2002. If submitting capability statements, it is your responsibility to ensure proper delivery of information.
- Place of Performance
- Address: NIH/NCI, 9000 Rockville Pike, Bethesda, MD 20892
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN00058696-W 20020414/020412213135 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |